The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
17 01 2020
Historique:
received: 05 08 2019
revised: 10 12 2019
pubmed: 15 12 2019
medline: 4 9 2020
entrez: 15 12 2019
Statut: ppublish

Résumé

Sodium taurocholate cotransporting polypeptide (NTCP) is expressed at the surface of human hepatocytes and functions as an entry receptor of hepatitis B virus (HBV). Recently, we have reported that epidermal growth factor receptor (EGFR) is involved in NTCP-mediated viral internalization during the cell entry process. Here, we analyzed which function of EGFR is essential for mediating HBV internalization. In contrast to the reported crucial function of EGFR-downstream signaling for the entry of hepatitis C virus (HCV), blockade of EGFR-downstream signaling proteins, including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), and signal transducer and activator of transcription (STAT), had no or only minor effects on HBV infection. Instead, deficiency of EGFR endocytosis resulting from either a deleterious mutation in EGFR or genetic knockdown of endocytosis adaptor molecules abrogated internalization of HBV via NTCP and prevented viral infection. EGFR activation triggered a time-dependent relocalization of HBV preS1 to the early and late endosomes and to lysosomes in concert with EGFR transport. Suppression of EGFR ubiquitination by site-directed mutagenesis or by knocking down two EGFR-sorting molecules, signal-transducing adaptor molecule (STAM) and lysosomal protein transmembrane 4β (LAPTM4B), suggested that EGFR transport to the late endosome is critical for efficient HBV infection. Cumulatively, these results support the idea that the EGFR endocytosis/sorting machinery drives the translocation of NTCP-bound HBV from the cell surface to the endosomal network, which eventually enables productive viral infection.

Identifiants

pubmed: 31836663
pii: S0021-9258(17)49936-4
doi: 10.1074/jbc.AC119.010366
pmc: PMC6970923
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Endosomal Sorting Complexes Required for Transport 0
LAPTM4B protein, human 0
Membrane Proteins 0
Oncogene Proteins 0
Organic Anion Transporters, Sodium-Dependent 0
Phosphoproteins 0
STAM protein, human 0
STAT Transcription Factors 0
Symporters 0
Viral Envelope Proteins 0
sodium-bile acid cotransporter 145420-23-1
ErbB Receptors EC 2.7.10.1
MAP Kinase Kinase 1 EC 2.7.12.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

800-807

Informations de copyright

© 2020 Iwamoto et al.

Références

Nat Med. 2005 May;11(5):515-21
pubmed: 15834425
Cell. 1988 Mar 11;52(5):675-84
pubmed: 2449972
Mol Cell. 2006 Mar 17;21(6):737-48
pubmed: 16543144
Traffic. 2011 Feb;12(2):201-17
pubmed: 21059162
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492
pubmed: 30952782
Nat Rev Clin Oncol. 2010 Sep;7(9):493-507
pubmed: 20551942
Histochem Cell Biol. 2007 May;127(5):541-53
pubmed: 17361439
J Cell Sci. 2017 Dec 15;130(24):4087-4096
pubmed: 29180516
Cell Host Microbe. 2013 Mar 13;13(3):302-13
pubmed: 23498955
Trends Cell Biol. 2014 Jan;24(1):26-34
pubmed: 24295852
Oncotarget. 2017 May 30;8(22):36869-36884
pubmed: 28415812
J Virol. 2005 Feb;79(3):1613-22
pubmed: 15650187
Elife. 2012 Nov 13;1:e00049
pubmed: 23150796
EMBO J. 2015 Feb 12;34(4):475-90
pubmed: 25588945
Cold Spring Harb Perspect Med. 2015 Aug 03;5(8):a021378
pubmed: 26238794
J Hepatol. 2014 Oct;61(4):867-75
pubmed: 24845614
Trends Cell Biol. 2016 May;26(5):352-366
pubmed: 26827089
Rev Med Virol. 2014 Jul;24(4):274-86
pubmed: 24888553
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16904-9
pubmed: 17940017
Exp Cell Res. 2007 Sep 10;313(15):3349-63
pubmed: 17643422
Sci Rep. 2017 Sep 6;7(1):10620
pubmed: 28878350
Front Microbiol. 2019 Jan 08;9:3257
pubmed: 30671048
Oncotarget. 2018 May 4;9(34):23681-23694
pubmed: 29805766
J Biol Chem. 2013 Nov 1;288(44):31715-27
pubmed: 24025329
J Virol. 1999 Mar;73(3):2052-7
pubmed: 9971786
J Virol. 2012 Oct;86(20):10935-49
pubmed: 22855500
J Virol. 2018 Mar 28;92(8):
pubmed: 29437960
J Biol Chem. 2012 Dec 7;287(50):41922-30
pubmed: 23095753

Auteurs

Masashi Iwamoto (M)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Mathematical Biology Laboratory, Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan.

Wakana Saso (W)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

Kazane Nishioka (K)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan.

Hirofumi Ohashi (H)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan.

Ryuichi Sugiyama (R)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Akihide Ryo (A)

Department of Microbiology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.

Mio Ohki (M)

Drug Design Laboratory, Yokohama City University Graduate School of Medical Life Science, Yokohama 230-0045, Japan.

Ji-Hye Yun (JH)

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, South Korea.

Sam-Yong Park (SY)

Drug Design Laboratory, Yokohama City University Graduate School of Medical Life Science, Yokohama 230-0045, Japan.

Takayuki Ohshima (T)

Faculty of Pharmaceutical Science at Kagawa Campus, Tokushima Bunri University, Kagawa 769-2193, Japan.

Ryosuke Suzuki (R)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Hideki Aizaki (H)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Masamichi Muramatsu (M)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

Shingo Iwami (S)

Mathematical Biology Laboratory, Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan.
Core Research for Evolutional Science and Technology (CREST) Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.
MIRAI, Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.

Camille Sureau (C)

Laboratoire de Virologie Moléculaire, Institut National de la Transfusion Sanguine, Paris 75739, France.

Takaji Wakita (T)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Koichi Watashi (K)

Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan kwatashi@nih.go.jp.
Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan.
Core Research for Evolutional Science and Technology (CREST) Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.
MIRAI, Japan Science and Technology Agency (JST), Saitama 332-0012, Japan.
Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH